Vedanta strikes deal with Janssen for IBD therapy

Janssen, a subsidiary of Johnson & Johnson, has entered a license agreement with Vedanta Biosciences to develop the latter firm's lead microbiome pharmaceutical candidate, VE202, for inflammatory bowel disease (IBD).